Global Grand Mal Seizure 麻豆原创 Research Report 2023

Publication ID:

PB503236994

Publication Date:

March 22, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Epilepsy is a group of neurological disorders characterized by brief, involuntary episodes of vigorous shaking of a part or complete body. The patient may experience loss or disturbance of consciousness and movements along with sensory or psychiatric disturbances. Grand mal seizures or tonic鈥揷lonic seizures are a type of generalized seizures, which affect the entire brain and are the most common type of epileptic seizures. Grand mal seizures are caused by neurotransmitter imbalances, which can also be influenced by fatigue, lack of sleep, hypertension, stress, intense lighting, rapid motion, blood sugar level, anxiety, etc. The grand mal seizures consist of two phases, the tonic phase and the clonic phase. The tonic phase involves loss of consciousness and muscle twitching and the phase usually last only for a few seconds. The clonic phase consists of rapid muscle contraction and relaxation resulting in convulsions.
Highlights
The global Grand Mal Seizure market was valued at US$ 20870 million in 2022 and is anticipated to reach US$ 24060 million by 2029, witnessing a CAGR of 2.4% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The Americas accounts for the significant market share owing to extensive use of medications and greater expenditure on the health care. Additionally, the fastest uptake of new technology and drugs in the US drives the global grand mal seizures market. The concentration of the major medical diagnostic device manufacturers in the developed regions is also adding fuel to the market. Europe is the second largest market due to a high disposable income and rising awareness about the grand mal seizures.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Grand Mal Seizure, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Grand Mal Seizure.
The Grand Mal Seizure market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Grand Mal Seizure market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Grand Mal Seizure companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Pfizer
Johnson & Johnson
UCB Celltech
Abbott Laboratories
GlaxoSmithKline
Novartis
Sanofi
Takeda
Teva Pharmaceutical
Segment by Type
Barbiturates
Hydantoin
Phenyltriazine
Iminostilbenes
Benzodiazepines
Aliphatic Carboxylic Acid
Others
Segment by Application
Hospitals
Clinics
Academic and Research Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Grand Mal Seizure companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Grand Mal Seizure 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Barbiturates
1.2.3 Hydantoin
1.2.4 Phenyltriazine
1.2.5 Iminostilbenes
1.2.6 Benzodiazepines
1.2.7 Aliphatic Carboxylic Acid
1.2.8 Others
1.3 麻豆原创 by Application
1.3.1 Global Grand Mal Seizure 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Academic and Research Centers
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Grand Mal Seizure 麻豆原创 Perspective (2018-2029)
2.2 Grand Mal Seizure Growth Trends by Region
2.2.1 Global Grand Mal Seizure 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Grand Mal Seizure Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Grand Mal Seizure Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Grand Mal Seizure 麻豆原创 Dynamics
2.3.1 Grand Mal Seizure Industry Trends
2.3.2 Grand Mal Seizure 麻豆原创 Drivers
2.3.3 Grand Mal Seizure 麻豆原创 Challenges
2.3.4 Grand Mal Seizure 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Grand Mal Seizure Players by Revenue
3.1.1 Global Top Grand Mal Seizure Players by Revenue (2018-2023)
3.1.2 Global Grand Mal Seizure Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Grand Mal Seizure 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Grand Mal Seizure Revenue
3.4 Global Grand Mal Seizure 麻豆原创 Concentration Ratio
3.4.1 Global Grand Mal Seizure 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Grand Mal Seizure Revenue in 2022
3.5 Grand Mal Seizure Key Players Head office and Area Served
3.6 Key Players Grand Mal Seizure Product Solution and Service
3.7 Date of Enter into Grand Mal Seizure 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Grand Mal Seizure Breakdown Data by Type
4.1 Global Grand Mal Seizure Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Grand Mal Seizure Forecasted 麻豆原创 Size by Type (2024-2029)
5 Grand Mal Seizure Breakdown Data by Application
5.1 Global Grand Mal Seizure Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Grand Mal Seizure Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Grand Mal Seizure 麻豆原创 Size (2018-2029)
6.2 North America Grand Mal Seizure 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Grand Mal Seizure 麻豆原创 Size by Country (2018-2023)
6.4 North America Grand Mal Seizure 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Grand Mal Seizure 麻豆原创 Size (2018-2029)
7.2 Europe Grand Mal Seizure 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Grand Mal Seizure 麻豆原创 Size by Country (2018-2023)
7.4 Europe Grand Mal Seizure 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Grand Mal Seizure 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Grand Mal Seizure 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Grand Mal Seizure 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Grand Mal Seizure 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Grand Mal Seizure 麻豆原创 Size (2018-2029)
9.2 Latin America Grand Mal Seizure 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Grand Mal Seizure 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Grand Mal Seizure 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Grand Mal Seizure 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Grand Mal Seizure 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Grand Mal Seizure 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Grand Mal Seizure 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Grand Mal Seizure Introduction
11.1.4 Pfizer Revenue in Grand Mal Seizure Business (2018-2023)
11.1.5 Pfizer Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Detail
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Grand Mal Seizure Introduction
11.2.4 Johnson & Johnson Revenue in Grand Mal Seizure Business (2018-2023)
11.2.5 Johnson & Johnson Recent Development
11.3 UCB Celltech
11.3.1 UCB Celltech Company Detail
11.3.2 UCB Celltech Business Overview
11.3.3 UCB Celltech Grand Mal Seizure Introduction
11.3.4 UCB Celltech Revenue in Grand Mal Seizure Business (2018-2023)
11.3.5 UCB Celltech Recent Development
11.4 Abbott Laboratories
11.4.1 Abbott Laboratories Company Detail
11.4.2 Abbott Laboratories Business Overview
11.4.3 Abbott Laboratories Grand Mal Seizure Introduction
11.4.4 Abbott Laboratories Revenue in Grand Mal Seizure Business (2018-2023)
11.4.5 Abbott Laboratories Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Detail
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Grand Mal Seizure Introduction
11.5.4 GlaxoSmithKline Revenue in Grand Mal Seizure Business (2018-2023)
11.5.5 GlaxoSmithKline Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Grand Mal Seizure Introduction
11.6.4 Novartis Revenue in Grand Mal Seizure Business (2018-2023)
11.6.5 Novartis Recent Development
11.7 Sanofi
11.7.1 Sanofi Company Detail
11.7.2 Sanofi Business Overview
11.7.3 Sanofi Grand Mal Seizure Introduction
11.7.4 Sanofi Revenue in Grand Mal Seizure Business (2018-2023)
11.7.5 Sanofi Recent Development
11.8 Takeda
11.8.1 Takeda Company Detail
11.8.2 Takeda Business Overview
11.8.3 Takeda Grand Mal Seizure Introduction
11.8.4 Takeda Revenue in Grand Mal Seizure Business (2018-2023)
11.8.5 Takeda Recent Development
11.9 Teva Pharmaceutical
11.9.1 Teva Pharmaceutical Company Detail
11.9.2 Teva Pharmaceutical Business Overview
11.9.3 Teva Pharmaceutical Grand Mal Seizure Introduction
11.9.4 Teva Pharmaceutical Revenue in Grand Mal Seizure Business (2018-2023)
11.9.5 Teva Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Pfizer
Johnson & Johnson
UCB Celltech
Abbott Laboratories
GlaxoSmithKline
Novartis
Sanofi
Takeda
Teva Pharmaceutical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.